ストックスクリーナーアプリを入手
2.31
2.12%
-0.05
前日終値:
$2.36
開ける：
$2.35
24時間の取引高:
2.46M
Relative Volume:
0.64
時価総額：
$688.35M
収益：
$38.03M
当期純損益:
$-146.40M
株価収益率:
-4.4423
EPS:
-0.52
ネットキャッシュフロー:
$-121.38M
1週間 パフォーマンス:
-5.33%
1か月 パフォーマンス:
-20.89%
6か月 パフォーマンス:
-11.49%
1年 パフォーマンス:
-49.01%
1日の値動き範囲:
$2.28
$2.36
1週間の範囲:
$2.28
$2.60
52週間の値動き範囲:
$2.11
$4.7499
Abcellera Biologics Inc Stock (ABCL) Company Profile
ABCL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.31 | 688.35M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK
AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com
Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa
Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India
Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com Australia
AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa
AbCellera biologics director John Montalbano acquires $57,499 in shares - Investing.com India
Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock - Simply Wall St
Ambarella, Builders Firstsource, Sherwin-Williams, AutoZone, AbCellera: Stock Moves That Shocked the Market - TipRanks
Director Makes Bold Move with Major Stock Purchase in AbCellera Biologics - TipRanks
Abcellera Biologics director Montalbano buys $140,568 in shares By Investing.com - Investing.com South Africa
Abcellera Biologics director Montalbano buys $140,568 in shares - Investing.com
Q1 Earnings Estimate for ABCL Issued By Bloom Burton - Defense World
Sanctuary Advisors LLC Decreases Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics’ (ABCL) Hold Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Hold on AbCellera stock, no price target change - Investing.com
Benchmark maintains Hold on AbCellera stock, no price target change By Investing.com - Investing.com UK
Stifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
AbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst Downgrade - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Thursday - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
AbCellera Biologics’ Earnings Call: Transition Amid Challenges - TipRanks
Abcellera stock hits 52-week low at $2.33 amid market challenges - Investing.com India
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ... - Yahoo Finance
AbCellera Biologics Reports 2024 Financial Results - TipRanks
Abcellera Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AbCellera Reports Full Year 2024 Business Results - sharewise
Abcellera Biologics earnings beat by $0.01, revenue fell short of estimates - Investing.com
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript - MSN
AbCellera Biologics Reports 2024 Financial Results and Growth - TipRanks
AbCellera Biologics Inc. SEC 10-K Report - TradingView
AbCellera Biologics Q4 2024 Earnings Preview - MSN
Earnings Scheduled For February 27, 2025 - Benzinga
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Trading Down 8.5%Here's What Happened - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap UpShould You Buy? - MarketBeat
This Healthcare Stock Rose Sharply On USPTO Issuance - The Globe and Mail
AbCellera reassigns COO to CTO role, dissolves position - Investing.com India
AbCellera Biologics Changes COO's Title to Technology Chief -February 18, 2025 at 12:57 pm EST - Marketscreener.com
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):